Separately, Zacks Investment Research raised Erytech Pharma from a sell rating to a hold rating in a report on Wednesday, July 10th.
Shares of NASDAQ ERYP opened at $5.65 on Thursday. The stock has a fifty day simple moving average of $6.38 and a two-hundred day simple moving average of $7.43. Erytech Pharma has a 1-year low of $5.30 and a 1-year high of $10.71. The firm has a market cap of $101.36 million, a price-to-earnings ratio of 2.32 and a beta of 1.49. The company has a current ratio of 7.26, a quick ratio of 7.19 and a debt-to-equity ratio of 0.01.
ERYTECH Pharma SA, a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia.
Featured Article: Discount Rate
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Erytech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erytech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.